Xarelto Ad’s Benefit Claims Need Renal Caveats, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Typography and graphics which highlight benefits but not risks makes a print ad for Xarelto to treat atrial fibrillation misleading, FDA tells Johnson & Johnson in an untitled letter.
You may also be interested in...
FDA Enforcement Letters On Rx Drug Promotions Plummet In 2013
OPDP Director Tom Abrams cautions against reading into the “snapshot.”
FDA Proposals For Studying Internet Promotions Raise Concerns
FDA should not delay draft guidance on Internet and social media promotional activities while it studies how consumer understanding of a drug’s safety and efficacy is affected by the techniques used to present information on branded websites, according to comments on the proposed studies.
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.